Prognosis in pancreatic cancer remains dismal, despite an abundance of investigational efforts and improved multimodality treatment. Extending survival is greatly hindered by delayed diagnosis, which limits therapeutic options. The UK National Institute for Health and Care Excellence (NICE) sought to develop a comprehensive evidence-based guideline to optimize practice and reduce variability in the diagnosis and treatment of pancreatic cancer.
The guideline conception was initiated by NICE and developed by a multidisciplinary committee of physicians, researchers, and lay members. The National Guideline Alliance established the committee, provided methodological support, undertook extensive systematic literature searches, appraised the evidence, and conducted meta-analyses and cost-effectiveness studies. Stakeholder input was solicited during a 6-week public consultation period. The committee disclosed conflicts of interests, and members were withdrawn from discussion according to NICE policy. NICE provided funding for the guideline development.